Skip to content
Checking whether you are signed in

Johnson & Johnson

JNJNew York Stock ExchangeFull coverage

Price
Loading your watchlists

AI-generatedPublished Nov 3, 2026, 5:28 PM UTC

Q3 fiscal 2026 edition

A free account unlocks one dossier edition a month.

Create a free account

Already have an account? Sign in

Summary

Free to read

Johnson & Johnson sells prescription drugs and medical devices, and its third quarter of fiscal 2026 showed new medicines such as TREMFYA, DARZALEX and CARVYKTI replacing the fast-shrinking STELARA: sales grew 5.9% to $25.4 billion and the company raised its full-year sales guidance again. Diluted EPS fell to $0.09 because of a $5.5 billion charge for a proposed ovarian talc settlement that still needs 95% of claimants to join, while the device business slowed for the third quarter running. The next test is 2027, when products with $4 billion to $4.5 billion of sales lose patent protection, by the CFO's count. Moatsight estimates revenue of about $105.3 billion and free cash flow of about $19.5 billion over the next four quarters.

In the full dossier

  1. Part 1In brief
  2. Part 2Business explainer
  3. Part 3Earnings
  4. Part 4Valuation and projections
  5. Part 5What changed

General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers